• Carolina B Meloto, Priscila O Serrano, Margarete C Ribeiro-DaSilva, and Célia M Rizzatti-Barbosa.
• Department of Prosthesis and Periodontology, Dental College of Piracicaba, State University of Campinas, Avenida Limeira 901, 13414-903 Piracicaba, São Paulo, Brazil.
• Arch. Oral Biol. 2011 Nov 1;56(11):1181-91.

AbstractThe field of temporomandibular disorders (TMD) is experiencing significant changes in terms of aetiology and treatment. Researchers and clinicians are becoming increasingly aware of the possibility that genetic variations may play a role in pain perception and onset of TMD. In this review, we purpose to briefly describe these allelic variants, how they may be involved in TMD pathophysiology and how they may affect TMD treatment. Studies have already pointed the association between TMD and genetic polymorphisms in the oestrogen receptor alpha, adrenergic receptor beta 2, serotonin receptor, serotonin transporter and catechol-O-methyltransferase genes, and other candidate genes continue to emerge. The main implication of these findings refers to the promising possibilities of "genome/omics-based personalised care", which consists of tailoring individual treatment based on personalised medication, depending on the individual genetic differences and early diagnosis and prognosis of the disorder, preventing acute pain conditions from becoming chronic. The following years of research shall focus on collecting and endorsing these findings if we are to provide patients in pain with efficient and successful TMD treatments.Copyright © 2011 Elsevier Ltd. All rights reserved.

17 keywords...

hide…